

(301) 366-4960

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

Other Events.

On July 23, 2015 Neuralstem, Inc. (“Company”) announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.’s patent infringement case with prejudice in favor of the Company in *StemCells, Inc. v. Neuralstem, Inc.* A copy of the press release, the memorandum opinion and the order of the court are attached to this report as Exhibits 99.01, 99.02 and 99.03, respectively.

Item 9.01.

Financial Statement and Exhibits.

Exhibit

No.	Description
99.01	Press Release Dated July 23, 2015.
99.02	Memorandum Opinion.
99.03	Order of the Court.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 23, 2015 Neuralstem, Inc.

/s/ Richard Garr
By: Richard Garr
Chief Executive
Officer

INDEX OF EXHIBITS

Exhibit

No.	Description
99.01	Press Release Dated July 23, 2015.
99.02	Memorandum Opinion.
99.03	Order of the Court.